Copyright © 2012 Yue Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. Antiplatelet Trialists' Collaboration, “Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” British Medical Journal, vol. 308, no. 6921, pp. 81–106, 1994. View at Google Scholar · View at Scopus
2. Antithrombotic Trialists' Collaboration, “Collaborate meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Google Scholar
3. M. Rafferty, M. R. Walters, and J. Dawson, “Anti-platelet therapy and aspirin resistance - Clinically and chemically relevant?” Current Medicinal Chemistry, vol. 17, no. 36, pp. 4578–4586, 2010. View at Google Scholar · View at Scopus
4. A. Pena, J. P. Collet, J. S. Hulot et al., “Can we override clopidogrel resistance?” Circulation, vol. 119, no. 21, pp. 2854–2857, 2009. View at Publisher · View at Google Scholar · View at Scopus
5. D. A. Gorog, J. M. Sweeny, and V. Fuster, “Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?” Nature Reviews. Cardiology, vol. 6, no. 5, pp. 365–373, 2009. View at Google Scholar · View at Scopus
6. D. N. Juurlink, T. Gomes, D. T. Ko et al., “A population-based study of the drug interaction between proton pump inhibitors and clopidogrel,” Canadian Medical Association Journal, vol. 180, no. 7, pp. 713–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
7. J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” New England Journal of Medicine, vol. 360, no. 4, pp. 354–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
8. J. Choi and J. C. Kermode, “New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects,” Molecular Interventions, vol. 11, no. 27, pp. 111–123, 2011. View at Google Scholar
9. K. J. Chen, L. D. Li, W. L. Weng, et al., “Blood stasis and research of activating blood circulation and eliminating stasis,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 3, no. 1, pp. 1–2, 2005. View at Google Scholar
10. K. J. Chen, “Exploration on the possibility of reducing cardiovascular risk by treatment with Chinese medicine recipes for promoting blood-circulation and relieving blood-stasis,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 28, no. 5, p. 389, 2008. View at Google Scholar · View at Scopus
11. K. J. Chen, M. Xue, and H. J. Yin, “The relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome,” Shoudu Yi Ke Da Xue Xue Bao, vol. 29, no. 3, pp. 266–269, 2008. View at Google Scholar
12. M. Xue, K. J. Chen, and H. J. Yin, “Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome,” Chinese Journal of Integrative Medicine, vol. 14, no. 4, pp. 267–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
13. Z. Wang, “Mechanism on modulating platelet function of activating blood circulation and removing stasis herbs,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 12, no. 9, pp. 567–570, 1992. View at Google Scholar · View at Scopus
14. Society of Cardiology and Chinese Association of the Integration of Traditional and Western Medicine, “The diagnostic criteria of TCM in coronary heart disease,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 11, no. 5, p. 257, 1991. View at Google Scholar
15. C. G. Fu, The study of diagnostic criterion on blood stasis for patients with coronary heart disease, Doctor Dissertation, Beijing University of Chinese Medicine, Beijing, China, 2011.
16. J. Z. Li, S. L. He, and H. L. Wang, Thrombosis Epidemiology, Science Press, Beijing, China, 1998.
17. F. Q. Xu, K. Y. Chen, X. C. Ma, et al., “Clinical observation on effect of xiongshao capsule on coronary heart disease with angina pectoris,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 23, no. 1, pp. 16–18, 2003. View at Google Scholar
18. J. Feng and S. L. Wang, “Effect of Fufang Danshen Diwan to Platelet Aggregation Function,” Chinese Journal of Misdiagnostics, vol. 6, no. 12, pp. 2261–2263, 2006. View at Google Scholar
19. J. B. Jiang, J. Yang, and C. Q. Deng, “Effect of Buyang huanwu decoction and its active fraction alkaloid and glycoside on platelet aggregation and cyclic nucleotide in rats,” Zhong Nan Yao Xue, vol. 6, no. 4, pp. 388–391, 2008. View at Google Scholar
20. J. Wang, J. Xu, and J. B. Zhong, “Effect of Radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 24, no. 4, pp. 312–316, 2004. View at Google Scholar · View at Scopus
21. D. S. Wang, F. P. Chen, S. L. He, et al., “Mechanism study on Dahuangzhechong pill anti-platelet activation,” Zhonghua Zhong Yi Yao Za Zhi, vol. 23, no. 9, pp. 818–821, 2008. View at Google Scholar
22. F. Liu, J. Li, and X. D. Wang, “Effect of tongxinluo capsule on platelet aggregation in patients with cerebral infarction,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 4, pp. 304–306, 2008. View at Google Scholar · View at Scopus
23. J. M. Li, Y. H. Zhao, G. C. Zhong, et al., “Synthesis of ferulic acid derivatives and their inhibitory effect on platelet aggregation,” Yao Xue Xue Bao, vol. 46, no. 3, pp. 305–310, 2011. View at Google Scholar
24. B. Shu, C. J. Zhou, Y. H. Ma, Y. J. Wang, and Q. Shi, “Research progress on pharmacological activities of the available compositions in Chinese medicinal herb Ligusticum chuanxiong,” Chinese Pharmacological Bulletin, vol. 22, no. 9, pp. 1043–1047, 2006. View at Google Scholar · View at Scopus
25. Y. R. Jiang, H. J. Yin, and L. Z. Li, “Treatment of non-ST-elevation acute coronary syndrome with propyl gallate,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 9, pp. 839–842, 2008. View at Google Scholar · View at Scopus
26. P. Chen, L. C. Yang, W. Y. Lei, and Z. Q. Shen, “Effects of polydatin on platelet aggregation and platelet cytosolic calcium,” Tianran Chan Wu Yan Jiu Yu Kai Fa, vol. 17, no. 1, pp. 21–25, 2005. View at Google Scholar
27. Q. Xia, T. X. Dong, H. Q. Zhan, et al., “Inhibition effect of curdione on platelet aggregation induced by ADP in rabbits,” Chinese Pharmacological Bulletin, vol. 22, no. 9, pp. 1151–1152, 2006. View at Google Scholar
28. J. J. Ma, Y. Song, M. Jia, and C. L. Li, “Effect of total flavone in sanguis draconis on platelet aggregation, thrombus formation and myocardial ischemia,” Zhong Cao Yao, vol. 33, no. 11, pp. 1008–1010, 2002. View at Google Scholar
29. Y. Yao, W. Y. Wu, A. H. Liu et al., “Interaction of salvianolic acids and notoginsengnosides in inhibition of ADP-induced platelet aggregation,” American Journal of Chinese Medicine, vol. 36, no. 2, pp. 313–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
30. Z. W. Jiang, L. J. Zhao, H. Zhang, et al., “Effect of hirudin injecton on antithrombosis in rats,” Ji Lin Da Xue Xue Bao (Yi Xue Ban), vol. 29, no. 4, pp. 417–418, 2003. View at Google Scholar
31. Z. Q. Guo, Z. Chen, L. Li, et al., “Effect of administration of Safflower yellow injection on the platelet aggregate rate and transforming growth factor-β1 in patients without ST elevation acute myocardial infarction,” Journal of Clinical Cardiology, vol. 26, no. 8, pp. 591–593, 2010. View at Google Scholar
32. S. C. Hsu-Lin, C. L. Berman, and B. C. Furie, “A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets,” Journal of Biological Chemistry, vol. 259, no. 14, pp. 9121–9126, 1984. View at Google Scholar · View at Scopus
33. A. D. Michelson and M. I. Furman, “Laboratory markers of platelet activation and their clinical significance,” Current Opinion in Hematology, vol. 6, no. 5, pp. 342–348, 1999. View at Publisher · View at Google Scholar · View at Scopus
34. H. Ikeda, Y. Takajo, K. Ichiki et al., “Increased soluble form of P-selectin in patients with unstable angina,” Circulation, vol. 92, no. 7, pp. 1693–1696, 1995. View at Google Scholar · View at Scopus
35. H. Shimomura, H. Ogawa, H. Arai et al., “Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction,” American Journal of Cardiology, vol. 81, no. 4, pp. 397–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
36. M. I. Furman, S. E. Benoit, M. R. Barnard et al., “Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease,” Journal of the American College of Cardiology, vol. 31, no. 2, pp. 352–358, 1998. View at Publisher · View at Google Scholar · View at Scopus
37. Y. Liu, H. J. Yin, Y. R. Jiang, et al., “Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 587–592, 2011. View at Google Scholar
38. Z. Q. Chen, L. Hong, and H. Wang, “Effect of danhong injection on platelet activation andinflammatory factors in patients of acute coronary syndrome after intervention therapy,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 29, no. 8, pp. 692–694, 2009. View at Google Scholar
39. Z. Q. Chen, L. Hong, and H. Wang, “Effect of tetramethylpyrazine on platelet activation and vascular endothelial function in patients with acute coronary syndrome undergoing percutaneous coronary intervention,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 27, no. 12, pp. 1078–1081, 2007. View at Google Scholar · View at Scopus
40. P. Xiong and L. Zhou, “Effect of compound danshen droplet pill on plasma endothelin and platelet α-granuleMembrane protein-140 in patients with unstable angina pectoris,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 7, no. 5, pp. 510–511, 2009. View at Google Scholar
41. L. Han, D. Y. Peng, F. Xu, et al., “Studies on anti-platelet activation effect and partial mechanisms of Taohong Siwu decoction,” Zhongguo Zhong Yao Za Zhi, vol. 35, no. 19, pp. 2609–2612, 2010. View at Google Scholar
42. H. M. Luo, D. Y. Fu, M. Z. Ren, et al., “Clinical study on tongxinluo capsule affecting activity of platelet's GP IIb/IIIa receptor in patients with coronary heart disease,” Zhong Cheng Yao, vol. 27, no. 2, pp. 181–183, 2007. View at Google Scholar
43. A. Kasirer-Friede, M. R. Cozzi, M. Mazzucato, L. de Marco, Z. M. Ruggeri, and S. J. Shattil, “Signaling through GP Ib-IX-V activates αIIbβ3 independently of other receptors,” Blood, vol. 103, no. 9, pp. 3403–3411, 2004. View at Publisher · View at Google Scholar · View at Scopus
44. D. S. Wang, F. P. Chen, S. L. He, et al., “Comparative research between plasma pharmacology and serum pharmacology of dahuang zhe chong pill,” Xue Shuan Yu Zhi Xue Xue, vol. 11, no. 1, pp. 5–8, 2005. View at Google Scholar
45. Y. L. Li, “Research progress in the treatment of cardiovascular diseases by Xue Fu Zhu Yu Tang,” Beijing Zhong Yi Yao, vol. 27, no. 3, pp. 228–230, 2008. View at Google Scholar
46. D. Yacoub, J. F. Théorêt, L. Villeneuve et al., “Essential role of protein kinase Cδ in platelet signaling, αIIbβ3 activation, and thromboxane A 2 release,” Journal of Biological Chemistry, vol. 281, no. 40, pp. 30024–30035, 2006. View at Publisher · View at Google Scholar · View at Scopus
47. Y. Nishizuka, “Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C,” Science, vol. 258, no. 5082, pp. 607–614, 1992. View at Google Scholar · View at Scopus
48. Y. M. Yang, X. X. Wang, J. Z. Chen, S. J. Wang, H. Hu, and H. Q. Wang, “Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity,” American Journal of Chinese Medicine, vol. 36, no. 3, pp. 603–613, 2008. View at Publisher · View at Google Scholar · View at Scopus
49. K. L. Kaplan and J. Owen, “Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo,” Blood, vol. 57, no. 2, pp. 199–202, 1981. View at Google Scholar · View at Scopus
50. C. W. Pumphrey and J. Dawes, “Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction,” American Journal of Cardiology, vol. 50, no. 6, pp. 1258–1261, 1982. View at Google Scholar · View at Scopus
51. A. Slungaard, “Platelet factor 4: a chemokine enigma,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 6, pp. 1162–1167, 2005. View at Publisher · View at Google Scholar · View at Scopus
52. W. Hope, T. J. Martin, C. N. Chesterman, and F. J. Morgan, “Human β-thromboglobulin inhibits PGI2 production and binds to a specific site in bovine aortic endothelial cells,” Nature, vol. 282, no. 5735, pp. 210–212, 1979. View at Google Scholar · View at Scopus
53. Y. Q. Kong, Z. Yao, M. L. Yun, et al., “Effect of danshen on angina pectoris and platlet function,” Gao Xue Ya Za Zhi, vol. 10, no. 5, pp. 451–453, 2002. View at Google Scholar
54. M. Yoshimura, T. Oshima, H. Hiraga et al., “Increased cytosolic free Mg2+ and Ca2+ in platelets of patients with vasospastic angina,” American Journal of Physiology, vol. 274, no. 2, pp. R548–R554, 1998. View at Google Scholar · View at Scopus
55. A. Fujinishi, K. Takahara, C. Ohba, Y. Nakashima, and A. Kuroiwa, “Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease,” Angiology, vol. 48, no. 6, pp. 515–521, 1997. View at Google Scholar · View at Scopus
56. R. X. Zhang, X. F. Lian, and N. Lian, “study progress of calcium antagonist of Chinese medicine on cardiovascular diseases,” Shanxi Zhong Yi Xue Yuan Xue Bao, vol. 22, no. 4, pp. 52–54, 1999. View at Google Scholar
57. W. M. Chen, M. Jin, and W. Wu, “study of Safflor yellow inhibit the PAF-induced platelet activation,” Zhongguo Yao Xue Za Zhi, vol. 35, no. 11, p. 741, 2000. View at Google Scholar
58. C. Chen and T. L. Yang, “TXA₂/PGI₂ and cardiovascular diseases,” Xian Dai Sheng Wu Yi Xue Jin Zhan, vol. 8, no. 11, pp. 2166–2172, 2008. View at Google Scholar
59. H. M. Xu, Q. Y. Liu, M. Dai, et al., “Effect of total glucosides of radix paeoniae rubra on platelet function of rats,” Hefei Gong Ye Da Xue Xue Bao (Zi Ran Ke Xue Ban), vol. 26, no. 1, pp. 141–144, 2003. View at Google Scholar
60. H. L. Gao, Y. K. Li, Y. Tong, and L. D. Li, “Comparative study on the protective effects of different Guanxin II formula on acute myocardial ischemia in dogs,” Zhong Yao Yao Li Yu Lin Chuang, vol. 23, no. 5, pp. 1–4, 2007. View at Google Scholar
61. Z. X. Lan, W. Z. Wang, Y. N. Ma, et al., “Experimental research on the influence of Taohong Siwu decoction on the TXB₂,6-keto-PGF1α in the blood stasis syndrom of rats,” Hua Xi Yao Xue Za Zhi, vol. 23, no. 6, pp. 687–688, 2008. View at Google Scholar
62. Y. Wu, H. B. Guo, T. J. Wang, et al., “Comparative study on effects of active ingredients of several traditional Chinese medicines on rabbit platelet aggregation in vitro,” Zhong Yao Lin Chuang Yao Li Xue Yu Zhi Liao Xue, vol. 12, no. 9, pp. 1047–1051, 2007. View at Google Scholar
63. W. G. Yu and L. N. Xu, “Effects of acetylsalvianolic acid A on arachidonic acid metabolism in platelets,” Yao Xue Xue Bao, vol. 33, no. 1, pp. 62–63, 1998. View at Google Scholar · View at Scopus
64. S. J. Yuan, Z. W. Zhang, Gao T. H., and J. H. Pu, “Mechanism research of Honghua injection antithrombotic function,” Zhongguo Zhong Yao Za Zhi, vol. 36, no. 11, pp. 1528–1529, 2011. View at Google Scholar
65. Z. Y. Wang, J. Z. Li, and C. G. Ruan, Basic Theory and Clinical of Thrombosis and Hemostasis, Shanghai Scientific and Technical Publishers, Shanghai, China, 2004.
66. S. H. Xu, “Cyclic nucleotides and blood platelet function,” Sheng li Ke Xue Jin Zhan, vol. 23, no. 4, pp. 318–322, 1992. View at Google Scholar · View at Scopus
67. G.G. Zhu, R. Z. Luo, and Z. X. Guo, “Advance of cardiotonic pill on inhibiting platelet activation and aggregation,” Zhongguo Xin Xue Guan Za Zhi, vol. 12, no. 2, pp. 149–151, 2007. View at Google Scholar
68. J. Yan and C. L. Qin, “Brief review on effects of Fufangdanshen prescription, Dan-shen and San-qi on the platelet functions,” Zhongguo Shi Yan Fangji Xue Za Zhi, vol. 9, no. 2, pp. 59–62, 2003. View at Google Scholar
69. H. Y. Pei and Y. Han, “Platelet activation through signal transduction–review,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 12, no. 5, pp. 704–707, 2004. View at Google Scholar · View at Scopus
70. J. Lu, Y. N. Yu, and R. B. Xu, Receptor Signaling System and Diseases, Shandong Science and Technology Press, Shandong, China, 1999.
71. J. M. E. M. Cosemans, I. C. A. Munnix, R. Wetzker, R. Heller, S. P. Jackson, and J. W. M. Heemskerk, “Continuous signaling via PI3K isoforms β and γ is required for platelet ADP receptor function in dynamic thrombus stabilization,” Blood, vol. 108, no. 9, pp. 3045–3052, 2006. View at Publisher · View at Google Scholar · View at Scopus
72. Z. Li, G. Zhang, G. C. Le Breton, X. Gao, A. B. Malik, and X. Du, “Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 30725–30731, 2003. View at Publisher · View at Google Scholar · View at Scopus
73. C. Kroner, K. Eybrechts, and J. W. N. Akkerman, “Dual regulation of platelet protein kinase B,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 27790–27798, 2000. View at Publisher · View at Google Scholar · View at Scopus
74. Z. S. Huang, C. L. Zeng, L. J. Zhu, L. Jiang, N. Li, and H. Hu, “Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase,” Journal of Thrombosis and Haemostasis, vol. 8, no. 6, pp. 1383–1393, 2010. View at Publisher · View at Google Scholar · View at Scopus
75. K. J. Chen, D. Z. Shi, H. Xu et al., “XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China,” Chinese Medical Journal, vol. 119, no. 1, pp. 6–13, 2006. View at Google Scholar · View at Scopus
76. A. García, “Clinical proteomics in platelet research: challenges ahead,” Journal of Thrombosis and Haemostasis, vol. 8, no. 8, pp. 1784–1785, 2010. View at Publisher · View at Google Scholar · View at Scopus
77. T. Thiele, L. Steil, S. Gebhard et al., “Profiling of alterations in platelet proteins during storage of platelet concentrates,” Transfusion, vol. 47, no. 7, pp. 1221–1233, 2007. View at Publisher · View at Google Scholar · View at Scopus
78. C. Banfi, M. Brioschi, G. Marenzi et al., “Proteome of platelets in patients with coronary artery disease,” Experimental Hematology, vol. 38, no. 5, pp. 341–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
79. L. Senzel, D. V. Gnatenko, and W. F. Bahou, “The platelet proteome,” Current Opinion in Hematology, vol. 16, no. 5, pp. 329–333, 2009. View at Publisher · View at Google Scholar · View at Scopus
80. X. F. Li, Y. R. Jiang, C. F. Wu, K. J. Chen, and H. J. Yin, “Study on the correlation between platelet function proteins and symptom complex in coronary heart disease,” Zhongguo Fen Zi Xin Zang Bing Xue Za Zhi, vol. 9, no. 6, p. 326, 2009. View at Google Scholar